{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:09:00Z","timestamp":1777331340242,"version":"3.51.4"},"reference-count":87,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD21\/0005\/0001"],"award-info":[{"award-number":["RD21\/0005\/0001"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.nefroe.2023.04.005","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T07:39:07Z","timestamp":1683272347000},"page":"676-687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lessons from SENCOVAC: A prospective study evaluating the response to SARS-CoV-2 vaccination in the CKD spectrum"],"prefix":"10.1016","volume":"43","author":[{"given":"Borja","family":"Quiroga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Soler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"de Sequera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2023.04.005_bib0440","doi-asserted-by":"crossref","unstructured":"AIRG-E, EKPF, ALCER, FRIAT, REDINREN, RICORS2040, SENEFRO, SET, ONT. CKD: The burden of disease invisible to research funders. Nefrologia 2022;42:65\u201384. https:\/\/doi.org\/10.1016\/j.nefro.2021.09.004.","DOI":"10.1016\/j.nefro.2021.09.004"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0445","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/ckj\/sfab170","volume":"15","author":"Ortiz","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0450","first-page":"gfac257","article-title":"ERA council. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association","author":"Ortiz","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0455","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0140-6736(14)60384-6","article-title":"Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure","volume":"383","author":"Ortiz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0460","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0465","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/ndt\/gfaa314","article-title":"Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA","volume":"36","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0470","doi-asserted-by":"crossref","first-page":"e1003","DOI":"10.1016\/S2214-109X(20)30264-3","article-title":"Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study","volume":"8","author":"Clark","year":"2020","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0475","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0480","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1093\/ndt\/gfaa261","article-title":"COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration","volume":"35","author":"Hilbrands","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0485","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.kint.2020.04.031","article-title":"COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain","volume":"98","author":"Goicoechea","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0490","doi-asserted-by":"crossref","first-page":"E2264","DOI":"10.3390\/jcm9072264","article-title":"The spectrum of clinical and serological features of COVID-19 in urban hemodialysis patients","volume":"9","author":"Stock da Cunha","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0495","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.nefroe.2020.06.013","article-title":"High prevalence of asymptomatic COVID-19 in haemodialysis: learning day by day in the first month of the COVID-19 pandemic","volume":"40","author":"Albalate","year":"2020","journal-title":"Nefrologia (Engl Ed)"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0500","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/1744-9987.13626","article-title":"Dynamic assessment of interleukin-6 during hemodialysis and mortality in coronavirus disease-19","volume":"25","author":"Quiroga","year":"2021","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0505","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1093\/ndt\/gfac234","article-title":"Impact of different COVID-19 waves on kidney replacement therapy epidemiology and mortality: REMER 2020","volume":"37","author":"Carriazo","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0510","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ckj\/sfaa112","article-title":"Kidney disease and electrolytes in COVID-19: more than meets the eye","volume":"13","author":"Carriazo","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0515","first-page":"205","article-title":"Madrid at the center of the Spanish COVID-19 pandemic: the result of ill-advised political decision-making","volume":"35","author":"Ortiz","year":"2021","journal-title":"Port J Nephrol Hypert"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0520","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/ckj\/sfaa163","article-title":"Often forgotten, transport modality to dialysis may be life-saving","volume":"13","author":"Fernandez-Prado","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0525","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gfaa191","article-title":"Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection","volume":"35","author":"Giaime","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0530","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0535","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0540","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0545","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0550","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase","volume":"385","author":"El Sahly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0555","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0560","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.ekir.2021.02.011","article-title":"Systematic review of safety and efficacy of COVID-19 vaccines in patients with kidney disease","volume":"6","author":"Glenn","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0565","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1093\/ndt\/gfab313","article-title":"Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study","volume":"37","author":"Quiroga","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0570","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/ckj\/sfac169","article-title":"Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study","volume":"15","author":"Quiroga","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0575","doi-asserted-by":"crossref","first-page":"827859","DOI":"10.3389\/fmed.2022.827859","article-title":"Immunogenicity and safety of COVID-19 vaccines in patients receiving renal replacement therapy: a systematic review and meta-analysis","volume":"9","author":"Ma","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0580","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3390\/vaccines10091395","article-title":"Efficacy and safety of COVID-19 vaccine in patients on renal replacement therapy","volume":"10","author":"Frittoli","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0585","doi-asserted-by":"crossref","first-page":"100178","DOI":"10.1016\/j.lanepe.2021.100178","article-title":"Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine","volume":"9","author":"Stumpf","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0590","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/ndt\/gfab227","article-title":"SARS-CoV-2 vaccination in patients receiving kidney replacement therapies: where are we now with the protective immune response?","volume":"36","author":"Toapanta","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0595","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1016\/j.vaccine.2022.09.067","article-title":"Immune response after COVID-19 vaccination among patients with chronic kidney disease and kidney transplant","volume":"40","author":"Trakarnvanich","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0600","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1097\/TP.0000000000004105","article-title":"An analysis of serological response and infection outcomes following Oxford-AstraZeneca (AZD1222) and Pfizer-BioNTech (mRNA BNT162b2) SARS-CoV-2 vaccines in kidney and kidney\u2013pancreas transplants","volume":"106","author":"Asderakis","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0605","doi-asserted-by":"crossref","first-page":"951576","DOI":"10.3389\/fimmu.2022.951576","article-title":"Immunogenicity and safety of two-dose SARS-CoV-2 vaccination via different platforms in kidney transplantation recipients","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0610","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s40620-022-01247-7","article-title":"Humoral immunogenicity and tolerability of heterologous ChAd\/BNT compared with homologous BNT\/BNT and ChAd\/ChAd SARS-CoV-2 vaccination in hemodialysis patients: a multicenter prospective observational study","volume":"35","author":"Haase","year":"2022","journal-title":"J Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0615","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1038\/s41467-021-25479-6","article-title":"Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum","volume":"12","author":"Bates","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0620","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.3390\/vaccines9101130","article-title":"Longitudinal humoral responses after COVID-19 vaccination in peritoneal and hemodialysis patients over twelve weeks","volume":"9","author":"Speer","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0625","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/ndt\/gfac007","article-title":"Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study","volume":"37","author":"Quiroga","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0630","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40620-022-01350-9","article-title":"Humoral immunity against Covid-19 six months after the Pfizer BNT162b2 vaccine in hemodialysis patients: data from five dialysis units. Is there a protective role for hemodiafiltration in the Covid-19 pandemic?","volume":"35","author":"Chuva","year":"2022","journal-title":"J Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0635","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2215\/CJN.12250921","article-title":"Seroresponse to SARS-CoV-2 vaccines among maintenance dialysis patients over 6 months","volume":"17","author":"Hsu","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0640","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/ndt\/gfac174","article-title":"Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis","volume":"37","author":"Verleye","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0645","doi-asserted-by":"crossref","first-page":"872","DOI":"10.2215\/CJN.01770222","article-title":"Humoral response to third dose of SARS-CoV-2 vaccines in the CKD spectrum","volume":"17","author":"Quiroga","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0650","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3390\/v14081822","article-title":"A systematic review and meta-analysis of serologic response following coronavirus disease 2019 (COVID-19) vaccination in solid organ transplant recipients","volume":"14","author":"Sakuraba","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0655","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.kint.2022.04.009","article-title":"Suboptimal antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients","volume":"101","author":"Al Jurdi","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0660","doi-asserted-by":"crossref","first-page":"14173","DOI":"10.1038\/s41598-022-18448-6","article-title":"Altered sialidase expression in human myeloid cells undergoing apoptosis and differentiation","volume":"12","author":"Hyun","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0665","doi-asserted-by":"crossref","first-page":"10357","DOI":"10.3389\/ti.2022.10357","article-title":"Enhanced SARS-CoV-2 antibody response after a third heterologous vector vaccine Ad26COVS1 dose in mRNA vaccine-primed kidney transplant recipients","volume":"36","author":"Schimpf","year":"2022","journal-title":"Transpl Int"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0670","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.ekir.2022.05.005","article-title":"Humoral response to heterologous SARS-CoV-2 vaccination in kidney transplant patients is heterogeneous and dose dependent","volume":"7","author":"Seija","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0675","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1038\/s41598-022-07574-w","article-title":"Immunogenicity of ChAdOx1 nCoV-19 vaccine after a two-dose inactivated SARS-CoV-2 vaccination of dialysis patients and kidney transplant recipients","volume":"12","author":"Bruminhent","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0680","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.1038\/s41467-022-33036-y","article-title":"Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial","volume":"13","author":"Mrak","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0685","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jamainternmed.2021.7372","article-title":"Comparison of SARS-CoV-2 antibody response 4 weeks after homologous vs heterologous third vaccine dose in kidney transplant recipients: a randomized clinical trial","volume":"182","author":"Reindl-Schwaighofer","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0690","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40620-022-01276-2","article-title":"Waning but persistent humoral response 6 months after the third dose of the mRNA BNT162b2 vaccine in hemodialysis and peritoneal dialysis patients","volume":"35","author":"Housset","year":"2022","journal-title":"J Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0695","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.1016\/j.vaccine.2022.08.065","article-title":"SARS-CoV-2 anti-spike antibodies after a fourth dose of COVID-19 vaccine in adult solid-organ transplant recipients","volume":"40","author":"Perrier","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0700","doi-asserted-by":"crossref","first-page":"e420","DOI":"10.1097\/TP.0000000000004219","article-title":"The fourth dose of CoronaVac vaccine results in a small increase of seroconversion and antibody values among kidney transplant recipients","volume":"106","author":"Cristelli","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0705","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.kint.2022.02.011","article-title":"A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients","volume":"101","author":"Benotmane","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0710","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfac007","article-title":"Humoral response after the fourth dose of the SARS-CoV-2 vaccine in the CKD spectrum: a prespecified analysis of the SENCOVAC study","author":"Quiroga","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0715","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1159\/000525309","article-title":"Humoral response and SARS-CoV-2 infection risk following the third and fourth doses of the BNT162b2 vaccine in dialysis patients","volume":"53","author":"Einbinder","year":"2022","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0720","doi-asserted-by":"crossref","first-page":"293","DOI":"10.34067\/KID.0006612021","article-title":"COVID-19 in patients with glomerular disease: follow-up results from the IRoc-GN international registry","volume":"3","author":"Waldman","year":"2022","journal-title":"Kidney360"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0725","doi-asserted-by":"crossref","first-page":"999704","DOI":"10.3389\/fimmu.2022.999704","article-title":"Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials","volume":"13","author":"Steiger","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0730","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3390\/vaccines10101738","article-title":"Long-term dynamic humoral response to SARS-CoV-2 mRNA vaccines in patients on peritoneal dialysis","volume":"10","author":"Quiroga","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0735","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2211283","article-title":"Six-month follow-up after a fourth BNT162b2 vaccine dose","author":"Canetti","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0740","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41581-022-00617-5","article-title":"Vaccination in patients with kidney failure: lessons from COVID-19","volume":"18","author":"Babel","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0745","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2215\/CJN.16621221","article-title":"Severity of COVID-19 after vaccination among hemodialysis patients: an observational cohort study","volume":"17","author":"Ashby","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0750","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1681\/ASN.2021060778","article-title":"Real-world effectiveness and immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in patients on hemodialysis","volume":"33","author":"Sibbel","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0755","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/ckj\/sfac135","article-title":"Evolving spectrum but persistent high mortality of COVID-19 among patients on kidney replacement therapy in the vaccine era: the Spanish COVID-19 KRT Registry","volume":"15","author":"Quiroga","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0760","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1111\/ajt.16701","article-title":"Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients","volume":"21","author":"Cucchiari","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0765","doi-asserted-by":"crossref","first-page":"150175","DOI":"10.1172\/JCI150175","article-title":"Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients","volume":"131","author":"Sattler","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0770","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1681\/ASN.2021040480","article-title":"Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients","volume":"32","author":"Bertrand","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0775","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/ajt.16958","article-title":"mTOR inhibitors improve both humoral and cellular response to SARS-CoV-2 messenger RNA BNT16b2 vaccine in kidney transplant recipients","volume":"22","author":"Netti","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0780","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1053\/j.ajkd.2021.06.002","article-title":"Humoral and cellular responses to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines administered to hemodialysis patients","volume":"78","author":"Broseta","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0785","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.kint.2021.07.005","article-title":"The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis","volume":"100","author":"Espi","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0790","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/ajt.16854","article-title":"Negative immune responses to two-dose mRNA COVID-19 vaccines in renal allograft recipients assessed with simple antibody and interferon gamma release assay cellular monitoring","volume":"22","author":"Crespo","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0795","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3390\/vaccines10060921","article-title":"Effect of a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine on humoral and cellular responses and serum anti-HLA antibodies in kidney transplant recipients","volume":"10","author":"Cassaniti","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0800","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.2215\/CJN.00830122","article-title":"Immune responses after a third dose of mRNA vaccine differ in virus-naive versus SARS-CoV-2-recovered dialysis patients","volume":"17","author":"Attias","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0805","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.cell.2022.01.027","article-title":"Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals","volume":"185","author":"Lederer","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0810","doi-asserted-by":"crossref","first-page":"908478","DOI":"10.3389\/fimmu.2022.908478","article-title":"Neutralizing potency of prototype and omicron RBD mRNA vaccines against omicron variant","volume":"13","author":"Zang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0815","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A bivalent omicron-containing booster vaccine against Covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0820","doi-asserted-by":"crossref","first-page":"ofab353","DOI":"10.1093\/ofid\/ofab353","article-title":"Suboptimal response to coronavirus disease 2019 messenger RNA vaccines in patients with hematologic malignancies: a need for vigilance in the postmasking era","volume":"8","author":"Agha","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0825","doi-asserted-by":"crossref","first-page":"n2481","DOI":"10.1136\/bmj.n2481","article-title":"Covid-19: antibody levels fall after second Pfizer dose, but protection against severe disease remains, studies indicate","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0830","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/s41591-022-01792-5","article-title":"Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies","volume":"28","author":"Bruel","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0835","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.17128","article-title":"Tixagevimab\/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave","author":"Al Jurdi","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0840","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.kint.2022.05.007","article-title":"Efficacy of anti-SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients","volume":"102","author":"Bertrand","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0845","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.kint.2022.07.008","article-title":"COVID-19 morbidity decreases with tixagevimab\u2013cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders","volume":"102","author":"Kaminski","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0850","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41591-021-01678-y","article-title":"An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies","volume":"28","author":"VanBlargan","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0855","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMc2201933","article-title":"Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2","volume":"386","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0860","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0865","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic","volume":"185","author":"Hoffmann","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.nefroe.2023.04.005_bib0870","unstructured":"EMA summary of product characteristics, paxlovid. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/paxlovid-epar-product-information_en.pdf [accessed 10.11.22]. EMA summary of product characteristics, veklury. n.d. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/veklury-epar-product-information_en.pdf [accessed 10.11.22]."}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251423000743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251423000743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:40:11Z","timestamp":1762598411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251423000743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":87,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2013251423000743"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2023.04.005","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lessons from SENCOVAC: A prospective study evaluating the response to SARS-CoV-2 vaccination in the CKD spectrum","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2023.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Nefrolog\u00eda.","name":"copyright","label":"Copyright"}]}}